Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4...
immunotherapy
Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results
- Released positive topline data from the VIRAGE Phase 2b study of VCN-01 (zabilugene almadenorepvec); expanded data to be presented...
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
Patients treated with Cylembio (imsapepimut and etimupepimut, adjuvanted) plus pembrolizumab achieved improvement in progression free survival (PFS) compared to patients...
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events
STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at...
Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma
SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading...
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments
Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company’s guidance...
Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction
New data from Eurofins Discovery show that Telomir-1 blocks enzymes that drive disease by turning off critical genes-highlighting its potential...
Tidewave Bio Reaches Key Regulatory Milestone with FDA INTERACT Meeting Scheduled for August 2025
Company advances development of first-in-class solid tumor immunotherapy platformLOS ANGELES, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Tidewave Bio, a biotechnology...
Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments
The final cohort of the single ascending dose (SAD) part of the Phase 1 AVALON trial initiated, with the SAD...
Caris Life Sciences Publishes Study Showing AI Signature-positive Breast Cancer Patients Live Almost Twice as Long as AI-negative Patients When Treated with a Checkpoint Inhibitor
Groundbreaking study in Communications Medicine highlights AI's role in transforming immunotherapy decisions and precision oncology IRVING, Texas, Aug. 6, 2025...
MyHealthTeam Now Hosts 11 Communities for People Living with Cancer
MyBladderCancerTeam and MyEndometrialCancer Team connect oncology patients with medically reviewed online content and support SAN FRANCISCO, Aug. 6, 2025 /PRNewswire/...
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
Acquisition to Include DANYELZA® (Naxitamab-gqgk), Further Broadening SERB’s Rare Oncology Product PortfolioTransaction Expands SERB’s Investment in the U.S.SERB to Commence...
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation...
CoRegen, Inc. Appoints Biotech Veteran Sonal Gupta, M.D., Ph.D., as Chief Medical Officer
HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- CoRegen, a biopharmaceutical company pursuing novel treatments for patients impacted by some of...
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapiesROCKVILLE, Md., July 31,...
OncoHost Named Top Precision Oncology Solution for 2025
BINYAMINA, Israel and CARY, N.C., July 30, 2025 /PRNewswire/ -- OncoHost, a leader in precision oncology leveraging proteomics and AI to...
IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025...
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical...
ORYZON Reports Financial Results and Corporate Update for Half-Year Ending June 30, 2025
Between December 2024 and July 2025, Oryzon secured financing totaling €52 M, approx. $61 M (€30.0 M from a capital...